Monitoring Xylazine and Fentanyl Co-Detection Through Urine Drug Testing
Overview
This study analyzes the co-occurrence of xylazine and fentanyl in urine drug tests across the U.S., revealing a 16.91% positivity rate for xylazine among fentanyl-positive specimens. The findings indicate regional variations in xylazine prevalence and concentration.
Background
Xylazine, a veterinary sedative not approved for human use, has emerged as an adulterant in the illicit drug supply, particularly in combination with fentanyl. Understanding the prevalence and concentration of xylazine in this context is important for clinical management.
Data Highlights
Region
Xylazine Positivity (%)
Change Over Time (%)
Eastern U.S.
19.63
8.52
Western U.S.
13.46
13.46
Key Findings
16.91% of fentanyl-positive urine drug tests were also positive for xylazine.
Xylazine concentrations peaked in 2023 before declining.
Copositivity with fentanyl increased by 13.46 percentage points in the Western U.S. over the study period.
Xylazine detection remains highest in the Eastern U.S. census regions.
Positive xylazine results necessitate specialized wound assessment and management.
Clinical Implications
Clinicians should consider testing for xylazine co-exposure in patients with fentanyl-positive urine drug tests.
Conclusion
The findings indicate the presence of xylazine in the drug supply, particularly in regions beyond traditional areas.
From signing bonuses and loan repayment programs to workforce initiatives and physician support resources, these trends reflect some of the strategies organizations are using to recruit and retain physicians in a competitive health care labor market.
